Literature DB >> 32227878

Chemical Synthesis and Biological Application of Modified Oligonucleotides.

Daniel A Glazier1,2, Junzhuo Liao1, Brett L Roberts1, Xiaolei Li1, Ka Yang1, Christopher M Stevens1, Weiping Tang1,2.   

Abstract

RNA plays a myriad of roles in the body including the coding, decoding, regulation, and expression of genes. RNA oligonucleotides have garnered significant interest as therapeutics via antisense oligonucleotides or small interfering RNA strategies for the treatment of diseases ranging from hyperlipidemia, HCV, and others. Additionally, the recently developed CRISPR-Cas9 mediated gene editing strategy also relies on Cas9-associated RNA strands. However, RNA presents numerous challenges as both a synthetic target and a potential therapeutic. RNA is inherently unstable, difficult to deliver into cells, and potentially immunogenic by itself or upon modification. Despite these challenges, with the help of chemically modified oligonucleotides, multiple RNA-based drugs have been approved by the FDA. The progress is made possible due to the nature of chemically modified oligonucleotides bearing advantages of nuclease stability, stronger binding affinity, and some other unique properties. This review will focus on the chemical synthesis of RNA and its modified versions. How chemical modifications of the ribose units and of the phosphatediester backbone address the inherent issues with using native RNA for biological applications will be discussed along the way.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32227878     DOI: 10.1021/acs.bioconjchem.0c00060

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  11 in total

1.  Fluorobenzene Nucleobase Analogues for Triplex-Forming Peptide Nucleic Acids.

Authors:  Vipin Kumar; Eriks Rozners
Journal:  Chembiochem       Date:  2021-12-20       Impact factor: 3.164

2.  Supramolecular "Click Chemistry" for Targeting in the Body.

Authors:  Christopher J Addonizio; Brant D Gates; Matthew J Webber
Journal:  Bioconjug Chem       Date:  2021-08-20       Impact factor: 6.069

3.  The infinite possibilities of RNA therapeutics.

Authors:  Evelyn C Mollocana-Lara; Ming Ni; Spiros N Agathos; Fernando A Gonzales-Zubiate
Journal:  J Ind Microbiol Biotechnol       Date:  2021-12-23       Impact factor: 4.258

Review 4.  Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies.

Authors:  Myrsini Chamakioti; Nikolaos Karantzelis; Stavros Taraviras
Journal:  Int J Mol Sci       Date:  2022-04-27       Impact factor: 6.208

Review 5.  Role of Lipid-Based and Polymer-Based Non-Viral Vectors in Nucleic Acid Delivery for Next-Generation Gene Therapy.

Authors:  Aniket Wahane; Akaash Waghmode; Alexander Kapphahn; Karishma Dhuri; Anisha Gupta; Raman Bahal
Journal:  Molecules       Date:  2020-06-22       Impact factor: 4.411

6.  High-quality RT-PCR with chemically modified RNA controls.

Authors:  Guangcheng Luo; Jun Zhang; Shun Zhang; Bei Hu; Lillian Hu; Zhen Huang
Journal:  Talanta       Date:  2020-11-11       Impact factor: 6.057

Review 7.  Modified Nucleic Acids: Expanding the Capabilities of Functional Oligonucleotides.

Authors:  Steven Ochoa; Valeria T Milam
Journal:  Molecules       Date:  2020-10-13       Impact factor: 4.411

8.  Development of Triantennary N-Acetylgalactosamine Conjugates as Degraders for Extracellular Proteins.

Authors:  Yaxian Zhou; Peng Teng; Nathan T Montgomery; Xiaolei Li; Weiping Tang
Journal:  ACS Cent Sci       Date:  2021-03-04       Impact factor: 14.553

9.  Modified Oligonucleotides: New Structures, New Properties, and New Spheres of Application.

Authors:  V G Metelev; T S Oretskaya
Journal:  Russ J Bioorg Chem       Date:  2021-04-26       Impact factor: 0.796

Review 10.  Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins.

Authors:  Jiayi Lin; Jinmei Jin; Yiwen Shen; Lijun Zhang; Gang Gong; Huiting Bian; Hongzhuan Chen; Dale G Nagle; Ye Wu; Weidong Zhang; Xin Luan
Journal:  Theranostics       Date:  2021-07-13       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.